ORION OYJ/ADR (OTCMKTS:ORINY) and Deutsche Wohnen (OTCMKTS:DWHHF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.
Risk & Volatility
ORION OYJ/ADR has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Deutsche Wohnen has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.
This table compares ORION OYJ/ADR and Deutsche Wohnen’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ORION OYJ/ADR||$1.23 billion||N/A||$255.44 million||$0.91||21.52|
|Deutsche Wohnen||$779.82 million||20.76||N/A||N/A||N/A|
ORION OYJ/ADR has higher revenue and earnings than Deutsche Wohnen.
ORION OYJ/ADR pays an annual dividend of $0.66 per share and has a dividend yield of 3.4%. Deutsche Wohnen does not pay a dividend. ORION OYJ/ADR pays out 72.5% of its earnings in the form of a dividend.
This table compares ORION OYJ/ADR and Deutsche Wohnen’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for ORION OYJ/ADR and Deutsche Wohnen, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ORION OYJ/ADR beats Deutsche Wohnen on 3 of the 4 factors compared between the two stocks.
About ORION OYJ/ADR
Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs. This segment provides proprietary drugs in the areas of central nervous system, oncology and critical care, and pulmonary care; generic prescription drugs, as well as self-care products, such as non-prescription medicines, basic ointments, and vitamins; proprietary and generic veterinary drugs; and APIs for generic and proprietary drugs, as well as offers contract manufacturing services for APIs. This segment also markets and sells veterinary drugs manufactured by other international companies. The Diagnostics segment develops, manufactures, and markets in vitro diagnostic test systems and tests for diagnosing diseases and monitoring treatment efficacy. Orion Oyj has a strategic alliance with Novan, Inc. to manufacture topical nitric oxide-releasing product candidates; and research collaboration with Fifth Corner Inc. to seek solutions to improve the quality of life of prostate cancer patients. The company was founded in 1917 and is headquartered in Espoo, Finland.
About Deutsche Wohnen
Deutsche Wohnen SE, a residential property company, develops and manages residential properties in Germany and Europe. The company operates through three segments: Residential Property Management, Disposals, and Nursing and Assisted Living. Its property portfolio consists of approximately 160,000 residential and commercial units, as well as operates 51 nursing home facilities with approximately 6,700 beds. The company manages and markets nursing and residential care homes, as well as provides services for the care of the senior citizens. Deutsche Wohnen SE was founded in 1924 and is headquartered in Berlin, Germany.
Receive News & Ratings for ORION OYJ/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORION OYJ/ADR and related companies with MarketBeat.com's FREE daily email newsletter.